8-K: Oruka Therapeutics Secures $200.5 Million in Private Placement to Advance Pipeline

Oruka Therapeutics has successfully raised approximately $200.5 million through a private placement to fund its research and development efforts.

Summary

• Oruka Therapeutics has entered into a securities purchase agreement for a private placement, expected to close on September 13, 2024.
• The private placement is anticipated to generate gross proceeds of approximately $200.5 million for the company.
• The financing includes the sale of 5,600,000 common shares at $23.00 per share, 2,439 Series A preferred shares at $23,000 per share, and pre-funded warrants to purchase 680,000 common shares at $22.999 per warrant.
• Each preferred share is convertible into 1,000 common shares, subject to stockholder approval and beneficial ownership limitations.
• The pre-funded warrants have an exercise price of $0.001 per share.
• Following the transaction, the company expects to have approximately 55.1 million common shares and common stock equivalents outstanding.
• The company intends to use the proceeds for research and development, general corporate expenses, and working capital.
• Oruka expects its cash to fund its operating plan through 2027.
• The company has engaged Jefferies, TD Securities, Leerink Partners, Stifel, and LifeSci Capital as placement agents.
• Oruka has also entered into a registration rights agreement to register the resale of the securities sold in the private placement.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful capital raise, promising preclinical data, and accelerated clinical timelines. The company appears to be well-positioned for future growth and development.

Positives

• The private placement provides significant funding for Oruka's operations and pipeline development.
• The participation of both new and existing investors indicates strong confidence in the company's prospects.
• The extended cash runway through 2027 provides financial stability for the company.
• The preclinical data for ORKA-001 suggests a potentially best-in-class profile with a long half-life.
• The accelerated clinical timelines for ORKA-001 and ORKA-002 indicate efficient progress in the company's pipeline.

Negatives

• The private placement involves the issuance of new shares, which could potentially dilute existing shareholders.
• The conversion of preferred stock is subject to stockholder approval, which introduces a degree of uncertainty.
• The company is reliant on the success of its clinical trials to achieve its goals.

Risks

• The closing of the private placement is subject to customary closing conditions, which could potentially delay or prevent the transaction.
• The company's ability to achieve its clinical and commercial goals is dependent on the success of its research and development efforts.
• The company's future performance is subject to market conditions and other external factors.
• There is a risk that the company may not be able to obtain the necessary stockholder approval for the conversion of the preferred stock.

Future Outlook

Oruka expects its cash to fund its operating plan through 2027 and anticipates sharing interim data from clinical trials in the coming years.

Management Comments

• Lawrence Klein, Orukas Chief Executive Officer, stated that the team has worked incredibly hard to progress our programs towards the clinic.
• Lawrence Klein also noted that the excellent pharmacokinetic profile in NHPs supports their conviction that ORKA-001 could provide patients greater freedom from disease than currently available agents.

Industry Context

The announcement comes as the biotechnology industry continues to see significant investment in companies developing novel therapies for chronic diseases. Oruka's focus on biologics for skin diseases aligns with the growing demand for more effective and convenient treatment options.

Comparison to Industry Standards

• Oruka's ORKA-001 is targeting IL-23p19, a well-validated target in psoriasis, similar to approved drugs like Skyrizi (risankizumab) and Tremfya (guselkumab).
• The company aims for less frequent dosing (once or twice per year) compared to current IL-23p19 inhibitors, which are typically dosed four to six times per year.
• Oruka's ORKA-002 targets IL-17A/F, similar to drugs like Bimzelx (bimekizumab), which has shown high PASI 100 rates in psoriasis.
• The company is also aiming for less frequent dosing with ORKA-002 compared to existing IL-17 inhibitors.
• The reported half-life of over 30 days for ORKA-001 in non-human primates is promising and suggests a potential for extended dosing intervals.

Stakeholder Impact

• Shareholders will experience potential dilution due to the issuance of new shares.
• Employees will benefit from the company's increased financial stability and ability to fund research and development.
• Patients may benefit from the development of new and potentially more effective treatments for chronic skin diseases.
• Investors will have the opportunity to participate in the company's growth and potential success.

Next Steps

• The company will close the private placement on or about September 13, 2024.
• Oruka will file a registration statement with the SEC to register the resale of the securities sold in the private placement.
• The company will seek stockholder approval for the conversion of the Series A preferred stock.
• Oruka will initiate first-in-human dosing of ORKA-001 in the first quarter of 2025.
• Oruka will initiate first-in-human dosing of ORKA-002 in the third quarter of 2025.
• The company will present preclinical data on ORKA-001 at the EADV Congress in September 2024.

Key Dates

Keywords

private placement, biologics, pipeline, clinical trials, psoriasis, ORKA-001, ORKA-002, half-life extended antibody, IL-23p19, IL-17A/F, dermatology, financing, biotechnology